MetabolicFDA Approved

Lixisenatide (Adlyxin)

Subcutaneous injection (daily)

Overview

A selective GLP-1 receptor agonist derived from exendin-4 with a modified C-terminal tail containing six lysine residues. Lixisenatide has a half-life of approximately 3 hours and primarily reduces postprandial glucose through potent delay of gastric emptying rather than fasting glucose reduction.

Mechanism of Action

It is designed for once-daily use as an add-on to basal insulin therapy in type 2 diabetes..

Research Summary & Key Findings

FDA-approved in 2016 for type 2 diabetes. GetGoal clinical trial program demonstrated effective postprandial glucose control. ELIXA cardiovascular outcomes trial confirmed cardiovascular safety. Available as a fixed-ratio combination with insulin glargine (Soliqua 100/33).

Clinical Status

FDA Approved

Lixisenatide (Adlyxin) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

Subcutaneous injection (daily)

Related Peptides in Metabolic

Semaglutide (Ozempic/Wegovy)

FDA Approved

A glucagon-like peptide-1 receptor agonist (GLP-1 RA) with 94% amino acid homology to native GLP-1. Semaglutide enhances...

View details

Tirzepatide (Mounjaro/Zepbound)

FDA Approved

A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activat...

View details

Retatrutide

In Clinical Trials

An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The gluc...

View details

AOD-9604

Investigational

A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine...

View details

Find a Provider

Find a verified provider who offers Lixisenatide (Adlyxin) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Lixisenatide (Adlyxin).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.